Novavax NVAX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Novavax (NVAX) Core Market Data and Business Metrics
Latest Closing Price
$5.98Price-Earnings Ratio
-4.86Total Outstanding Shares
160.84 Million SharesDividend
$0.11 Per Share 12 Times a YearSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
700 Quince Orchard Road, Gaithersburg, MD, 20878
Historical Stock Splits
If you bought 20 shares of NVAX before May 10, 2019, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| May 10, 2019 | 1-for-20 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 3,953,391 Shares | 9.5 | 3/14/2025 | 37,551,429 Shares |
| 6,142,661 Shares | 6.39 | 2/28/2025 | 39,225,752 Shares |
| 2,790,574 Shares | 12.7 | 2/14/2025 | 35,447,513 Shares |
| 3,990,272 Shares | 8.76 | 1/31/2025 | 34,935,605 Shares |
| 6,071,445 Shares | 6.27 | 1/15/2025 | 38,069,559 Shares |
| 3,213,269 Shares | 11.49 | 12/31/2024 | 36,917,946 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-30.72 Million |
| Net Cash Flow From Financing Activities | $260.58 Million |
| Exchange Gains/Losses | $-7.80 Million |
| Net Cash Flow From Investing Activities, Continuing | $-204.04 Million |
| Net Cash Flow From Operating Activities | $-87.26 Million |
| Net Cash Flow From Financing Activities, Continuing | $260.58 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Selling, General, and Administrative Expenses | $337.19 Million |
| Basic Average Shares | $152.19 Million |
| Benefits Costs and Expenses | $858.78 Million |
| Net Income/Loss | $-187.50 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income Tax Expense/Benefit, Current | $12.31 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-212.78 Million |
| Comprehensive Income/Loss Attributable To Parent | $-212.78 Million |
| Comprehensive Income/Loss | $-212.78 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-25.28 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $1.12 Billion |
| Inventory | $8.75 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Current Assets | $1.13 Billion |
| Other Current Liabilities | $1.05 Billion |
| Liabilities And Equity | $1.56 Billion |
Historical Dividends
Current dividend: $0.11 Per Share 12 Times a Year
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||